Viking Therapeutics (VKTX) said Tuesday it has signed a deal with CordenPharma to manufacture and supply both the active pharmaceutical ingredient and finished product for Viking's VK2735 program for obesity.
Under the terms of the deal, Viking said it will pay $150 million between 2025 and 2028 to CordenPharma, which has committed to provide an annual supply of over 1 billion oral tablets of VK2735 as well as 100 million autoinjectors and 100 million vial and syringe products for the subcutaneous formulation of VK2735.
Viking said it retains ownership of all global rights to VK2735, its investigational dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for metabolic disorders like obesity.
The company said it is conducting a phase 2 oral dosing trial of VK2735 and expects to begin a phase 3 study for the subcutaneous formulation in Q2.
Viking's stock was down 2% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.